Climb Bio (CLYM) Other Non-Current Liabilities (2021 - 2023)

Climb Bio (CLYM) reported Other Non-Current Liabilities of $22000.0 for Q4 2023, down 35.29% quarter-over-quarter from $34000.0 in Q3 2023.

Climb Bio (CLYM) Other Non-Current Liabilities (2021 - 2023) Analysis & Trends

Climb Bio has reported Other Non-Current Liabilities for 2 years, with the latest figure at $22000.0 in Q4 2023.

For the quarter ending Q4 2023, Other Non-Current Liabilities changed N/A year-over-year to $22000.0; the trailing twelve-month figure through Dec 2023 stood at $22000.0 (changed N/A YoY), and the FY2023 full-year result was $22000.0, changed N/A from the prior year.
Other Non-Current Liabilities for Q4 2023 stood at $22000.0, down from $34000.0 in the prior quarter.
The five-year high for Other Non-Current Liabilities was $87000.0 in Q1 2023, with the low at $7000.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Climb Bio	740.73 Mn	740.73 Mn	-

Download Data